医学
依瓦布拉定
荟萃分析
心力衰竭
内科学
心脏病学
心率
血压
作者
Hongbing Wan,Tieqiu Huang,Hongzhou Zhang,Qinghua Wu
标识
DOI:10.1016/j.clinthera.2020.10.005
摘要
Abstract Purpose Ivabradine reduces heart rate (HR) in patients with heart failure (HF). However, its effect on cardiac remodeling is not obvious. The goal of this study was to explore the extra effect of ivabradine on cardiac remodeling in patients with HF. Methods We searched PubMed from database inception to January 31, 2020, Cochrane and Embase from database inception to February 2, 2020, and Web of Science and ClinicalTrials.gov from database inception to February 3, 2020, for randomized controlled trials on ivabradine treatments in patients with stable symptomatic HF, left ventricular ejection fraction (LVEF) Findings Of 2277 trials, 9 trials fulfilled the inclusion criteria. A total of 1523 patients were enrolled in 9 studies. There were 796 participants in the ivabradine group and 727 participants in the control group. The duration of follow-up ranged from 6 weeks to 19.6 months. The mean (SD) age of the participants was 59.7 (11.2) years, and 1187 participants (77.9%) were men. Therapy with ivabradine was related to reversing cardiac remodeling with a significant increase in LVEF (MD = 3.04%; 95% CI, 2.07%–4.00%; p Implications In patients with stable symptomatic HF, LVEF
科研通智能强力驱动
Strongly Powered by AbleSci AI